ストックスクリーナーアプリを入手
1.23
2.38%
-0.03
プレマーケット:
1.23
前日終値:
$1.26
開ける：
$1.25
24時間の取引高:
329.46K
Relative Volume:
0.69
時価総額：
$44.61M
収益：
-
当期純損益:
$-35.58M
株価収益率:
-0.4642
EPS:
-2.65
ネットキャッシュフロー:
$-42.82M
1週間 パフォーマンス:
-13.99%
1か月 パフォーマンス:
-11.83%
6か月 パフォーマンス:
+12.84%
1年 パフォーマンス:
-20.13%
1日の値動き範囲:
$1.20
$1.26
1週間の範囲:
$1.20
$1.4774
52週間の値動き範囲:
$0.808
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
ITRM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
1.23 | 44.61M | 0 | -35.58M | -42.82M | -2.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-05-28 | アップグレード | Gabelli & Co | Sell → Hold |
| 2021-03-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | ダウングレード | Gabelli & Co | Buy → Sell |
| 2019-12-11 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Iterum Therapeutics Plc (ITRM) 最新ニュース
Sulopenem Etzadroxil/Probenecid (orlynvah) by Iterum - openPR.com
Iterum outlines ORLYNVAH's market potential with exclusivity through 2034 - MSN
Iterum Therapeutics appoints Joseph Whalen to its Board By Investing.com - Investing.com Canada
Iterum Therapeutics appoints Joseph Whalen to its Board - Investing.com
Iterum Therapeutics Appoints New Board Members - TipRanks
Sanctuary Advisors LLC Invests $35,000 in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Down 5.3% in January - Defense World
Iterum Therapeutics faces Nasdaq non-compliance issue - MSN
A stock that deserves closer examination: Iterum Therapeutics Plc (ITRM) - US Post News
Iterum Therapeutics Plc [ITRM] Insider Activity: An Update for Investors - Knox Daily
ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down - MSN
A better buy-in window may exist right now for Iterum Therapeutics Plc (ITRM) - SETE News
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results -February 10, 2025 at 10:41 am EST - Marketscreener.com
Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2024 Earnings Call Transcript - Insider Monkey
Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: - GuruFocus.com
Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance
Iterum Therapeutics Highlights FDA Approval and Financial Progress - TipRanks
Earnings call transcript: Iterum Therapeutics reports Q4 2024 results and stock surges - MSN
Iterum Therapeutics PLC Files For Mixed Shelf Of Up To $150 Million -February 07, 2025 at 04:42 pm EST - Marketscreener.com
Iterum Therapeutics Plc’s Shares Reel: 14.34% Quarterly Revenue Decline Amid 40.59M Market Cap - The InvestChronicle
Iterum Therapeutics PLC reports results for the quarter ended December 31Earnings Summary - TradingView
Iterum Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Iterum Therapeutics plc (ITRM) reports earnings - Quartz
Iterum Therapeutics plc SEC 10-K Report - TradingView
ForexTV | Small Business Resources - ForexTV.com
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Iterum's Landmark UTI Drug ORLYNVAH Powers Financial Turnaround in Q4 Report - StockTitan
Iterum Therapeutics Plc (ITRM) Shares Down Despite Recent Market Volatility - The News Heater
Iterum Therapeutics (ITRM) Expected to Announce Quarterly Earnings on Friday - Defense World
Is Iterum Therapeutics Plc (ITRM) a good investment opportunity? - US Post News
Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025 - Marketscreener.com
Iterum Therapeutics (NASDAQ:ITRM) Stock Quotes, Forecast and News Summary - Benzinga
Iterum Pharmaceuticals Earnings: Q4 Results and Pipeline Updates Coming February 7 - StockTitan
Short Interest in Iterum Therapeutics plc (NASDAQ:ITRM) Drops By 10.3% - Defense World
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - The Eastern Progress Online
Iterum Therapeutics stock hits 52-week high at $2.35 By Investing.com - Investing.com UK
Metrics That Matter About Iterum Therapeutics Plc (NASDAQ: ITRM) - Stocks Register
Iterum Therapeutics Regains Full Nasdaq Compliance - The Manila Times
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA - GuruFocus.com
Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2024 Earnings Call Transcript - Insider Monkey
Iterum Therapeutics plc (ITRM) Quarterly 10-Q Report - Quartzy
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ... - Yahoo Finance
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges - GuruFocus.com
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ... By GuruFocus - Investing.com Canada
Iterum Therapeutics’ Strategic Advances with ORLYNVAH Approval - TipRanks
ARMISTICE CAPITAL, LLC Acquires New Stake in Iterum Therapeutics PLC - GuruFocus.com
Earnings Flash (ITRM) ITERUM THERAPEUTICS Reports Q3 Loss $-0.24 - Marketscreener.com
Iterum Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Iterum Therapeutics sees cash runway into 2025 - TipRanks
Iterum Therapeutics Plc (ITRM) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):